S&P Futures
4,233.00 +23.25 (+0.55%) Dow Futures
33,459.00 +155.00 (+0.47%) Nasdaq Futures
13,398.25 +87.00 (+0.65%) Russell 2000 Futures
1,987.60 +11.30 (+0.57%) Crude Oil
93.35 -0.99 (-1.05%) Gold
1,810.70 +3.50 (+0.19%)
Immunocore Holdings plc (IMCR)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 53.95 |
| Open | 54.72 |
| Bid | 27.00 x 1100 |
| Ask | 57.95 x 1000 |
| Day's Range | 51.30 - 55.03 |
| 52 Week Range | 18.43 - 56.80 |
| Volume | |
| Avg. Volume | 199,025 |
| Market Cap | 2.304B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings Date | Aug 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4,412.36 |
- GlobeNewswire
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp revenues of £27.7 million ($33.7 million) in Q2 2022 Transitioned all patients in Germany early access program to commercial supply in May of 2022 Protocol finalized for randomized Phase 2/3 trial of tebentafusp in advanced melanoma with first pati
- GlobeNewswire
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that it will
- Zacks
Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.
